Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,428.00
Bid: 12,432.00
Ask: 12,436.00
Change: -82.00 (-0.66%)
Spread: 4.00 (0.032%)
Open: 12,556.00
High: 12,562.00
Low: 12,420.00
Prev. Close: 12,510.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI)

27 May 2014 11:49

RNS Number : 1157I
Bank of America Merrill Lynch
27 May 2014
 



FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITYRule 8.5 of the Takeover Code (the "Code")

 

1.

KEY INFORMATION

(a)

Name of exempt principal trader:

Bank of America Merrill Lynch

(b)

Name of offeror/offeree in relation to whoserelevant securities this form relates:Use a separate form for each offeror/offeree

AstraZeneca PLC

(c)

Name of the party to the offer with which exempt principal trader is connected:

Pfizer Inc

(d)

Date dealing undertaken:

23/05/2014

(e)

Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

Yes

 

2.

DEALINGS BY THE EXEMPT PRINCIPAL TRADER

(a)

Purchases and sales

Class of relevant security

Purchases/sales

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Common - ISIN GB0009895292

Purchase

855,516

43.28 GBP

42.17 GBP

Common - ISIN GB0009895292

Purchase

252,253

484.2 SEK

472.3 SEK

Common - ISIN GB0009895292

Sale

836,886

43.28 GBP

42.26 GBP

Common - ISIN GB0009895292

Sale

248,808

481.6 SEK

473.81 SEK

 

(b)

Derivatives transactions (other than options)

Class of relevant security

Product descriptione.g. CFD

Nature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

Common - ISIN GB0009895292

Swaps

Long

2

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

6

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

20

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

68

42.732 GBP

Common - ISIN GB0009895292

Swaps

Short

551

42.471 GBP

Common - ISIN GB0009895292

Swaps

Long

3

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

3

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

1

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

9

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

11

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

57

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

6

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

7

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

13

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

10

42.732 GBP

Common - ISIN GB0009895292

Swaps

Long

10

42.732 GBP

Common - ISIN GB0009895292

Swaps

Short

1,500

42.354 GBP

Common - ISIN GB0009895292

Swaps

Long

36,585

43.077 GBP

Common - ISIN GB0009895292

Swaps

Short

36,585

42.434 GBP

Common - ISIN GB0009895292

Swaps

Short

58,840

42.434 GBP

Common - ISIN GB0009895292

Swaps

Short

85,863

42.434 GBP

Common - ISIN GB0009895292

Swaps

Long

62,717

43.12 GBP

Common - ISIN GB0009895292

Swaps

Long

100,000

43.192 GBP

Common - ISIN GB0009895292

Swaps

Short

1,703

42.311 GBP

Common - ISIN GB0009895292

Swaps

Long

426

42.492 GBP

Common - ISIN GB0009895292

Swaps

Long

1,277

42.492 GBP

Common - ISIN GB0009895292

Swaps

Short

136

42.311 GBP

Common - ISIN GB0009895292

Swaps

Long

33

42.492 GBP

Common - ISIN GB0009895292

Swaps

Long

103

42.492 GBP

Common - ISIN GB0009895292

Swaps

Short

4,034

42.311 GBP

Common - ISIN GB0009895292

Swaps

Long

1,009

42.492 GBP

Common - ISIN GB0009895292

Swaps

Long

3,025

42.492 GBP

Common - ISIN GB0009895292

Swaps

Short

600

42.371 GBP

Common - ISIN GB0009895292

Swaps

Long

600

43.091 GBP

Common - ISIN GB0009895292

Swaps

Short

13,703

42.311 GBP

Common - ISIN GB0009895292

Swaps

Long

3,423

42.492 GBP

Common - ISIN GB0009895292

Swaps

Long

10,280

42.492 GBP

Common - ISIN GB0009895292

Swaps

Long

2,500

42.466 GBP

Common - ISIN GB0009895292

Swaps

Long

2,266

43.28 GBP

Common - ISIN GB0009895292

Swaps

Long

143

43.083 GBP

Common - ISIN GB0009895292

Swaps

Short

96

43.283 GBP

Common - ISIN GB0009895292

Swaps

Short

82,500

42.41 GBP

Common - ISIN GB0009895292

Swaps

Short

150,000

42.41 GBP

Common - ISIN GB0009895292

Swaps

Short

179

43.286 GBP

Common - ISIN GB0009895292

Swaps

Short

104

43.283 GBP

Common - ISIN GB0009895292

Swaps

Long

164,325

42.94 GBP

Common - ISIN GB0009895292

Swaps

Long

10,000

42.286 GBP

Common - ISIN GB0009895292

Swaps

Long

20,000

42.286 GBP

Common - ISIN GB0009895292

Swaps

Long

10,000

43.015 GBP

Common - ISIN GB0009895292

Swaps

Long

10,000

43.015 GBP

Common - ISIN GB0009895292

Swaps

Long

600

481.328 SEK

Common - ISIN GB0009895292

Swaps

Short

600

474.471 SEK

Common - ISIN GB0009895292

Swaps

Short

68,815

42.563 GBP

Common - ISIN GB0009895292

Swaps

Long

68,815

42.576 GBP

Common - ISIN GB0009895292

Swaps

Long

1,561

42.576 GBP

Common - ISIN GB0009895292

Swaps

Short

1,000

42.318 GBP

Common - ISIN GB0009895292

Swaps

Long

1,000

42.076 GBP

 

(c)

Options transactions in respect of existing securities

(i)

Writing, selling, purchasing or varying

Class ofrelevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number ofsecurities to which option relates

Exercise priceper unit

Typee.g. American, European etc.

Expiry date

Option money paid/ received per unit

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

 

(ii)

Exercising

Class of relevant security

Product descriptione.g. call option

Number of securities

Exercise Price per unit

N/A

N/A

N/A

N/A

 

(d)

Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealinge.g. subscription, conversion

Details

Price per unit (if applicable)

N/A

N/A

N/A

N/A

 

The currency of all prices and other monetary amounts should be stated.Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional classof relevant security dealt in.

 

3.

OTHER INFORMATION

 

(a)

Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state "none"

None

 

(b)

Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) The voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none"

None

 

Date of disclosure:

27/05/2014

Contact name:

Stacy Otieno

Telephone number:

0207 995 1335

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory InformationService and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.The Panel's Market Surveillance Unit is available for consultation in relation to the Code'sdealing disclosure requirements on +44 (0)20 7638 0129.The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERBGGDURSDBGSR
Date   Source Headline
27th Jan 20207:00 amRNSAstraZeneca to recover brazikumab (MEDI2070)
20th Jan 20207:00 amRNSFDA grants Lynparza Priority Review for PROfound
20th Jan 20207:00 amRNSImfinzi, tremelimumab granted ODD in liver cancer
13th Jan 20207:01 amRNSLynparza granted FDA Priority Review for PAOLA-1
13th Jan 20207:00 amRNSUpdate on Epanova Phase III STRENGTH trial
6th Jan 20207:01 amRNSFarxiga granted FDA heart failure Priority Review
6th Jan 20207:00 amRNSLokelma approved in China for hyperkalaemia
2nd Jan 20203:00 pmRNSTotal Voting Rights
30th Dec 20197:00 amRNSUS FDA approved Lynparza for pancreatic cancer
23rd Dec 20197:00 amRNSTriple-combination approved in China for COPD
23rd Dec 20197:00 amRNSEnhertu (trastuzumab deruxtecan) approved in US
20th Dec 20197:00 amRNSAstraZeneca divests rights to Arimidex and Casodex
17th Dec 20196:06 pmRNSFDA panel backs Lynparza use for pancreatic cancer
16th Dec 20197:00 amRNSSeroquel rights agreement complete: Europe, Russia
12th Dec 20197:00 amRNSImfinzi approved in China for Stage III NSCLC
11th Dec 20191:00 pmRNSTrastuzumab deruxtecan achieves ORR of 60.9%
5th Dec 20197:00 amRNSLynparza approved in China for 1L BRCAm ovarian
3rd Dec 20197:00 amRNSAstraZeneca divests Seroquel rights: US and Canada
2nd Dec 20193:00 pmRNSBlock listing Interim Review
2nd Dec 20193:00 pmRNSTotal Voting Rights
29th Nov 20197:00 amRNSImfinzi granted FDA Priority Review for SCLC
21st Nov 20196:15 pmRNSCalquence approved in CLL in the US
15th Nov 20197:00 amRNSQtrilmet approved in the EU for treatment of T2D
14th Nov 20197:00 amRNSFDA accepts regulatory submission for selumetinib
12th Nov 20197:00 amRNSAnifrolumab demonstrated superiority in TULIP 2
11th Nov 20197:00 amRNSRoxadustat pooled analyses: no increased CV risk
8th Nov 20197:00 amRNSRoxadustat significantly increased haemoglobin
6th Nov 20192:10 pmRNSCalquence data to show improved progression-free
1st Nov 20193:00 pmRNSTotal Voting Rights
30th Oct 20197:00 amRNSAstraZeneca divests rights to Seroquel and
28th Oct 20193:31 pmRNSImfinzi and Imfinzi plus tremelimumab delayed
24th Oct 20197:00 amRNSAstraZeneca year-to-date and Q3 2019 results
21st Oct 20197:00 amRNSFarxiga approved in the US to reduce the risk of
17th Oct 20197:00 amRNSTrastuzumab deruxtecan granted FDA Priority Review
4th Oct 20193:04 pmRNSHolding(s) in Company
4th Oct 20193:00 pmRNSHolding(s) in Company
4th Oct 20197:00 amRNSFasenra approved in the US for self-administration
3rd Oct 20194:00 pmRNSDirector Declaration
1st Oct 20193:00 pmRNSTotal Voting Rights
1st Oct 20197:05 amRNSAstraZeneca divests rights for Losec to Cheplaphar
1st Oct 20197:00 amRNSUpdate on US regulatory review of PT010 in COPD
30th Sep 20193:30 pmRNSLynparza more than doubled the time without
30th Sep 20197:00 amRNSTagrisso is the only 1st-line treatment for EGFR-
30th Sep 20197:00 amRNSLynparza improved the time women lived without
23rd Sep 20197:00 amRNSQtrilmet recommended for approval in EU by CHMP
18th Sep 20197:00 amRNSAstraZeneca amends collaboration with Ironwood
9th Sep 20198:38 amRNSImfinzi is first immunotherapy to show both
4th Sep 20197:11 amRNSTagrisso approved in China as a 1st-line treatment
2nd Sep 20193:00 pmRNSTotal Voting Rights
2nd Sep 20197:05 amRNSBrilinta reduced the risk of cardiovascular events

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.